GET DAILY SIGNALSWhy Is Valneva SE (VALN) Stock Up +4.06% Today?
Key Takeaways
- Valneva SE (VALN) climbed +4.06% to roughly $5.89, up $0.23 from the prior session's close of $5.66.
- Primary catalyst: Positive Phase 2 results for S4V2, the company's tetravalent Shigella (shigellosis) vaccine candidate, continued to drive buying interest.
- Clinical details: Two Phase 2 studies—one in infants in Kenya and one in U.S. adults—reported a favorable safety profile, strong immunogenicity, and a met primary endpoint.
- Market backdrop: The advance was company-specific, with European equity indices trading weaker, underscoring the strength of the pipeline-driven move.
- What traders are watching next: The company's development path for S4V2, upcoming nine-month financial results, and updates on its partnered Lyme disease vaccine.
- For additional detail on this stock, explore Price Targets, Earnings, and Forecast pages.
- Interested in automated strategies? Explore the Trending AI Robots page for curated, market-tested trading bots.
Opening Summary
Valneva SE (VALN), a French specialty vaccine company developing and commercializing prophylactic vaccines against infectious diseases, moved sharply higher in Tuesday's session. The stock advanced +4.06%, adding about $0.23 to trade near $5.89, compared with a prior close of $5.66. The move was driven by sustained investor enthusiasm around favorable Phase 2 clinical data for the company's Shigella vaccine candidate, S4V2, announced a day earlier—a program with no currently licensed competitor globally.
Positive Phase 2 Data for the S4V2 Shigella Vaccine
The dominant catalyst behind the rally is the announcement of encouraging Phase 2 results for S4V2, Valneva's tetravalent bioconjugate vaccine candidate against shigellosis. The company reported a favorable safety and tolerability profile across two separate trials, with results that investors interpreted as validating the program's clinical potential.
In an infant immunogenicity and safety study conducted in Kenya, two dose levels were evaluated against a meningococcal control vaccine in roughly 110 infants aged nine months. The candidate demonstrated a generally mild-to-moderate adverse event profile and produced significant antibody responses against all four targeted Shigella serotypes, with levels remaining above baseline six months after vaccination.
A separate controlled human infection model (CHIM) study, run across U.S. clinical sites with approximately 120 healthy adults, met its pre-specified primary endpoint—vaccinated participants showed a statistically significant reduction in shigellosis incidence compared with placebo. The U.S. FDA has previously granted the program Fast Track designation, reflecting the serious unmet medical need, as no licensed shigellosis vaccine currently exists despite the disease being a leading cause of fatal diarrheal illness worldwide.
Why the Market Rewarded the Readout
The size of the commercial opportunity underpinned the market reaction. Shigella causes an estimated 165 million infections globally each year, including tens of millions among children under five, yet the prevention landscape remains empty of an approved vaccine. A favorable readout therefore materially de-risks a pipeline asset with first-mover potential.
At the same time, the response was tempered by caution. Valneva's Chief Scientific Officer noted that, while the results were positive and encouraging, further clinical evaluation and optimization of the dose and vaccination schedule remain necessary. Analysts echoed this, suggesting additional Phase 2 work could be required before advancing to Phase 3. That nuance likely kept the rally measured rather than explosive.
Market Context and Trading Activity
The advance stood out as a company-specific, pipeline-driven move rather than a product of broader sector strength. European equity benchmarks, including the CAC 40 and Stoxx Europe 600, traded lower during the period, meaning Valneva's gains ran against the prevailing macro backdrop. Trading in the U.S.-listed American depositary shares is relatively thin compared with larger-cap peers, which can amplify percentage swings in either direction on clinical news. The move reflects a repricing of the S4V2 program's probability of success more than a rotation into the vaccine sector as a whole.
What Comes Next for VALN
Investors will now focus on how Valneva refines the S4V2 development path, including dose selection and trial design ahead of any potential Phase 3 program. The company's nine-month 2026 financial results are expected later this month, offering a broader look at commercial performance and cash position. Separately, the partnered Lyme disease vaccine candidate (VLA15) with PFE remains a key watch item, given its regulatory progress in Europe.
Risks remain: Valneva continues to post operating losses, and any delay or setback in optimizing the S4V2 program—or in the broader pipeline—could reverse sentiment quickly. The stock's low float and news-sensitive profile mean volatility is likely to persist around clinical and regulatory milestones.
Trending AI Robots
Tickeron's Trending AI Robots page curates the strongest-performing automated trading bots under current market conditions. Tickeron offers hundreds of AI-powered bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and traded symbols. Only the top performers are featured, helping traders identify signals aligned with today's markets. Explore the page to see which strategies are currently leading.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
VALN in upward trend: price may jump up because it broke its lower Bollinger Band on October 22, 2026
VALN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 38 of 43 cases where VALN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 69 cases where VALN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on VALN as a result. In 72 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for VALN just turned positive on October 28, 2026. Looking at past instances where VALN's MACD turned positive, the stock continued to rise in 36 of 45 cases over the following month. The odds of a continued upward trend are 80%.
Following a +6.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where VALN advanced for three days, in 171 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VALN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for VALN entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. VALN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 62 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.441) is normal, around the industry mean (3.498). P/E Ratio (-3.061) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.559) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VALN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement